Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2019
Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyFederica Morano, Salvatore Corallo, Sara Lonardi, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trialStefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Future Oncology (London, England)|May 31, 2018
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRCCarmine Pinto, Nicola Normanno, Armando Orlandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2020
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancerPaolo Manca, Salvatore Corallo, Giovanni Randon, et al.
Cancer Medicine|June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatmentGuido Giordano, Michele Milella, Matteo Landriscina, et al.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino studyAlessandra Raimondi, Massimo Di Maio, Federica Morano, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Pageof 24